PocketECG, MediLynx’s FDA approved remote monitoring systems: PocketECG Unified Arrhythmia Diagnostic System will be used for continuous streaming and analysis of full-disclosure ECG data, oxygen saturation, resting heart rate, patient symptoms and arrhythmia. The device is cleared by the FDA for the use of its data to analyze, measure and report QT intervals.
PLANO, Texas, March 31, 2020 /PRNewswire/ — MediLynx Cardiac Monitoring, LLC, a national remote monitoring provider and a technology leader in deep learning artificial intelligence (AI), today announced the introduction of dedicated services based on its PocketECG systems to help hospitals manage COVID-19 patients in all stages of the infection. PocketECG is the world’s only platform that provides online transmission of full-disclosure data to the cloud, powered by an advanced deep learning AI processing engine. PocketECG is known for its unique data points, depth of analysis and comprehensive reporting. The transmitted full-disclosure signal and diagnostic reports are accessible through any web-enabled device from anywhere, anytime.
The services are aimed to support healthcare providers in 3 areas of care.
- Management of pre-hospitalized patients:
+ Oxygen saturation (SpO2)
+ Resting heart rate (continuously: 24/7)
+ Symptoms
+ Full-disclosure ECG and arrhythmia analysis (continuously 24/7: for cardiac patients) - Management of patients undergoing pharmacotherapy and treatment
+ QT prolongation (every 3 hours: 24/7)
+ Ventricular arrhythmia (continuously: 24/7)
+ Oxygen saturation (SpO2: during daytime),
+ Resting heart rate (continuously: 24/7)
+ Symptoms (24/7)
+ Other arrhythmia, including AF and AV blocks (continuously: 24/7) - Management of post-treatment patients
+ Oxygen saturation (SpO2)
+ Resting heart rate (continuously: 24/7)
+ Symptoms
+ Full-disclosure ECG and arrhythmia analysis for cardiac patients (continuously: 24/7)
“MediLynx’s PocketECG is a comprehensive solution that assists telehealth providers in remote monitoring of both lung and heart functionality and can be used in the practice of telehealth” said Marek Dziubinski, PhD and inventor of PocketECG. “Furthermore, our technology allows physicians to track QT interval changes and monitor variations in the frequency of ventricular arrhythmia without any interaction from the patient, and when the patient is asleep. All these functionalities make it the most complete ECG monitoring solution for managing patients with SARS-CoV-2 in all stages of the infection.”
Peter Pellerito, Chief Executive Officer of MediLynx, added, “Our dedicated staff of certified cardiac technicians will support patients 24 hours a day, 7 days a week.”
About MediLynx Arrhythmia Diagnostics
MediLynx Cardiac Monitoring LLC, a leader in cardiac monitoring, delivering cardiac diagnostic solutions and service to enable the best possible care for patients. The company’s team of highly trained technicians and customer care specialists work seamlessly to provide round-the-clock monitoring, reporting, training and support for cardiology practices and their patients. To learn more, visit www.medilynx.com
About PocketECG Systems
PocketECG systems are integrated telehealth solutions that will allow for monitoring of a patient’s ECG parameters, heart rhythm, with inputs for symptoms, oxygen saturation and blood pressure remotely with a smartphone-sized device, for up to 30 days. The PocketECG platform captures, classifies and streams every heartbeat to the cloud where deep learning AI algorithms are applied against a full data set for more accurate detection of abnormalities and arrhythmia. Patients record symptoms and other measurements with the device allowing for direct correlation between all collected data points. All data is streamed via mobile telephone network to a secure online clinician portal and to a cardiac monitoring center for constant monitoring, evaluation, and urgent notifications. To learn more, visit www.pocketecg.com.
Jeff Normand
Marketing Director
774-321-0800
jeff.normand@medilynx.com
SOURCE MediLynx
